TRIAXONE 0.5g I.V. price in UAE

Overview

Welcome to Dwaey, specifically on TRIAXONE 0.5g I.V. Injection/Powder for page.
This medicine contains an important and useful components, as it consists of Ceftriaxone (as sodium).
TRIAXONE 0.5g I.V. is available in the market in concentration 500mg/Vial and in the form of Injection/Powder for.

JULPHAR (GULF PHARMACEUTICAL INDUSTRIES) is the producer of TRIAXONE 0.5g I.V. and it is imported from UAE, The most popular alternatives of TRIAXONE 0.5g I.V. are listed downward .

Mode Of Action

Ceftriaxone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.

Indication

Pneumonia
Meningitis
Acute otitis media
Lyme disease
Typhoid fever
Otitis media
Pelvic inflammatory disease
Septicemia
Skin and Skin-Structure Infections
Gonorrhea
Respiratory tract infections
Urinary tract infections
Bone and Joint Infections
Chlamydia infection
Surgical Prophylaxis

Precaution

History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection. Lactation: Drug enters breast milk in low concentrations; use with caution

Side Effects

>10% Induration after IM injection (5-17%) 1-10% Eosinophilia (6%)
Thrombocytosis (5%)
Diarrhea (3%)
Elevated hepatic transaminases (3%)
Leukopenia (2%)
Rash (2%)
Increased blood urea nitrogen (BUN) (1%)
Induration at IV site (1%)
Pain (1%) <1% Agranulocytosis
Anaphylaxis
Anemia
Basophilia
Bronchospasm
Candidiasis
Chills
Diaphoresis
Dizziness
Dysgeusia
Flushing
Gallstones
Glycosuria
Headache
Hematuria
Hemolytic anemia
Increased alkaline phosphatase or bilirubin
Increased creatinine
Jaundice
Leukocytosis
Lymphocytosis
Lymphopenia
Monocytosis
Nausea
Neutropenia
Phlebitis
Prolonged or decreased prothrombin time (PT)
Pruritus
Renal stones
Serum sickness
Thrombocytopenia
Urinary casts
Vaginitis
Vomiting

Contra indication

Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid. Potentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.